Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer

Inclusion Criteria: * Pathologically confirmed, locally advanced, malignancy of the esophagus; the cancer may involve the stomach up to 5 cm; based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatment * Stage T1-4aN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup: * Computed tomography (CT) chest/abdomen with contrast * Positron emission tomography (PET)/CT of the whole-body or skull base to mid-thigh * Patients must have regional adenopathy and have undergone endoscopic biopsy with endoscopic ultrasound (EUS)-proven peri-esophageal nodal involvement * Subjects must have had no prior therapy for cancer of the esophagus * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * White blood cell count \>= 3.0 K/cu mm * Absolute neutrophil count \>= 1.5 K/cu mm * Platelets \>= 100 K/cu mm * Hemoglobin \>= 8.0 g/dl (The use of transfusion or other invention to achieve Hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable) * Total bilirubin =\< 1.5 X institutional upper limit of normal * Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for subjects with creatinine levels above institutional normal * Serum ferritin \< 2.0 X institutional upper limit of normal * Woman of childbearing potential, a negative serum or urine pregnancy test * Willingness to use adequate contraception for 12 months after completion of all therapy * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Subjects with cervical or Siewert 3 esophageal carcinoma, that are recommended by the multi-disciplinary tumor board to have treatment other than tri-modality chemo-radiation therapy (RT) followed by esophagectomy * Subjects with AJCC 7th edition stage TxN0, T4b, and M1 disease * Prior systemic chemotherapy for esophageal cancer; prior chemotherapy for another malignancy is allowable as long as it has been \> 2 years since completion of therapy for previous malignancy * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study * Prior chest radiation or radiation for esophageal cancer * History of other malignancy in the past 2 years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma * Medical contraindications to esophagectomy * Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother, breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this study * Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol * Subjects with evidence of iron overload * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol * Patients with renal insufficiency; glomerular filtration rate (GFR) \< 60 * Adult patients who require monitored anesthesia for magnetic resonance imaging (MRI) scanning * Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to gadolinium (Gd) contrast material * Subjects with known hepatic insufficiency or cirrhosis